Surmodics

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Surmodics reports Q1 growth, FDA hurdles, and strategic partnerships

Surmodics navigates FDA challenges with the SurVeil application while focusing on cost-saving measures and revenue growth strategies for fiscal 2023.
The company's strong technology foundation, partnership with Abbott, and customer acceptance of key products position it well for future growth.
Despite challenges in FDA approval and spending reductions, Surmodics remains committed to innovation, regulatory compliance, and strategic partnerships.
Opportunities in product commercialization, revenue growth, and asset preservation offer avenues for overcoming challenges and driving long-term success.

Surmodics reports solid Q2 growth, navigates FDA approvals and revenue challenges

Surmodics shows strong performance in medical device sales and strategic objectives execution.
Challenges include In Vitro Diagnostics revenue decline and revised fiscal guidance.
Opportunities lie in significant sales growth projections and regulatory milestones.
Financial stability maintained through cash utilization plan and spending reduction measures.
Overall, Surmodics navigates growth and challenges with a focus on FDA approvals and revenue growth.

Surmodics excels in Q3 with robust revenue growth and strategic partnerships

Surmodics delivered exceptional Q3 results, driven by strong revenue growth and operational achievements, setting the stage for continued success.
The company's focus on cash flow generation, disciplined expense management, and strategic partnerships with Abbott bode well for future growth and profitability.
While facing challenges such as COVID-related impacts and revenue sharing negotiations, Surmodics remains poised to capitalize on opportunities for growth and innovation.
With a solid financial position, expanded revenue guidance, and readiness to support Abbott's commercial initiatives, Surmodics is well-positioned for a promising future.

Surmodics reports robust Q4 earnings, eyes growth amidst challenges

Surmodics delivered strong financial performance in Q4 2023 and fiscal 2023, driven by revenue growth and operational improvements.
While facing challenges such as competitive dynamics and projected losses in fiscal 2024, the company is well-positioned to capitalize on opportunities.
Strategic achievements, product advancements, and financial stability position Surmodics for continued growth and market success in the coming year.
Emphasis on innovation, market expansion, and cost management will be crucial for Surmodics to navigate challenges and leverage growth opportunities.

Surmodics reports robust Q1 growth, eyes new product launches

Surmodics' Q1 2024 performance reflects strong revenue growth, operational efficiency, and successful product launches, positioning the company for continued success in the medical device and diagnostics markets.
While challenges such as incremental expenses and pricing dynamics exist, Surmodics' focus on innovation, financial discipline, and market responsiveness presents opportunities for sustained growth and competitive advantage.
With a strategic outlook towards driving revenue growth, expanding product offerings, and optimizing expenses, Surmodics aims to navigate challenges and capitalize on opportunities for long-term success and market leadership.

Surmodics reports robust Q2 growth, eyes profitability amid challenges

Surmodics' Q2 2024 performance reflects revenue growth, improved profitability, and product innovation, underpinned by strong R&D focus and strategic partnerships.
While facing challenges in achieving profitability and providing clear guidance for fiscal 2025, the company remains optimistic about growth opportunities and market expansion.
With a focus on enhancing margins, expanding product offerings, and leveraging partnerships, Surmodics is poised for continued growth and innovation in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

Surmodics' (SRDX) CEO Gary Maharaj on Q2 2020 Results - Earnings Call Transcript

SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Surpasses Q2 Earnings and Revenue Estimates

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

SurModics (SRDX) Down 22.1% Since Last Earnings Report: Can It Rebound?

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q1 2020 Results - Earnings Call Transcript

SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Surpasses Q1 Earnings Estimates

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q4 2019 Results - Earnings Call Transcript

SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Q4 Earnings and Revenues Surpass Estimates

Aphria

BioLife Solutions

Medical Products Industry Outlook: Prospects Seem Promising

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

Crocs

e.l.f. Beauty

Hilltop Holdings

Top Ranked Momentum Stocks to Buy for September 26th

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will SurModics (SRDX) Gain on Rising Earnings Estimates?

Bristol-Myers

Genesco

Zumiez

Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.

Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks

Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2019 Results - Earnings Call Transcript

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.

Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised

Perrigo

PRGO vs. SRDX: Which Stock Is the Better Value Option?

PRGO or SRDX: Which Is the Better Value Stock Right Now?

Investors need to pay close attention to Surmodics (SRDX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?

Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?

Helen of Troy

Lexinfintech Hlds

Herman Miller

Veeco Instruments

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

New Analyst Coverage Puts Spotlight on These Five Stocks

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q2 2019 Results - Earnings Call Transcript

Surmodics Inc said in a securities filing Monday that it was working with the Food and Drug Administration to clarify how the agency's Friday warning.

News for Surmodics Stock (SRDX)